Medical Treatment ~ Breast Cancer
~ Genetics of Breast & Ovarian Cancer

Primarily chemotherapy, but includes all treatment modalities except surgery and radiation.

List was last updated on Dec 9, 2019 @ 12:56 pm.


    • BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
    • Lee A, Moon BI, Kim TH.
    • Ann Lab Med. 2020 Mar;40(2):114-121. doi: 10.3343/alm.2020.40.2.114.
    • Review

    Introductory article:

    From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer.

    • Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    • Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.
    • Br J Cancer. 2019 Dec 9. doi: 10.1038/s41416-019-0674-4. [Epub ahead of print]
    • Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    • Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.
    • Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]
    • Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    • Exman P, Mallery RM, Lin NU, Parsons HA.
    • NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.
    • Hype or hope? The strange case of platinum salts' renaissance in breast cancer.
    • Corvaja C, Garutti M, Gerratana L, Pelizzari G, Puglisi F.
    • Expert Rev Anticancer Ther. 2019 Nov 27. doi: 10.1080/14737140.2019.1699066. [Epub ahead of print]
    • Editorial
    • Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    • Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J.
    • Oncologist. 2019 Nov 25. pii: theoncologist.2019-0493. doi: 10.1634/theoncologist.2019-0493. [Epub ahead of print]
    • Targeted Therapies for Triple-Negative Breast Cancer.
    • Lyons TG.
    • Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.
    • Review
    • Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy.
    • Christian N, Zabor EC, Cassidy M, Flynn J, Morrow M, Gemignani ML.
    • Ann Surg Oncol. 2019 Nov 15. doi: 10.1245/s10434-019-08038-8. [Epub ahead of print]
    • Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy.
    • Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor JC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W.
    • JNCI Cancer Spectr. 2019 Nov 9; pkz085. doi: 10.1093/jncics/pkz085. eCollection 2019 Nov.
    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer.
    • Saito S, Nakazawa K, Nagahashi M, Ishikawa T, Akazawa K.
    • Per Med. 2019 Nov 6. doi: 10.2217/pme-2018-0141. [Epub ahead of print]
    • The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
    • Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P.
    • NPJ Breast Cancer. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019.
    • Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
    • Fitzpatrick A, Tutt A.
    • Ther Adv Med Oncol. 2019 Nov 1;11:1758835919882581. doi: 10.1177/1758835919882581. eCollection 2019.
    • Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy.
    • Kumeta T, Matsunuma R, Yamaguchi K, Hayami R, Tsuneizumi M.
    • Case Rep Oncol. 2019 Oct 29;12(3):814-819. doi: 10.1159/000503858. eCollection 2019 Sep-Dec.
    • Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
    • Walker-Smith TL, Peck J.
    • Nurs Womens Health. 2019 Oct 25. pii: S1751-4851(19)30188-6. doi: 10.1016/j.nwh.2019.09.003. [Epub ahead of print]
    • Review
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    • Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    • Biochim Biophys Acta Mol Basis Dis. 2019 Oct 19:165561. doi: 10.1016/j.bbadis.2019.165561. [Epub ahead of print]
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising.
    • [No author given]
    • FORCE. XRAYS. 2019 Oct 4.

    Original research:

    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

    • Who Should Consider Genetic Counseling and Testing for Breast and Ovarian Cancer? Guidelines Have Expanded.
    • [No author given]
    • My Gene Counsel. 2019 Oct 3.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer.
    • Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S.
    • Nutr Cancer. 2019 Oct 1:1-10. doi: 10.1080/01635581.2019.1670216. [Epub ahead of print]
    • Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
    • Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
    • Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer.
    • Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.
    • Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
    • Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.
    • Nat Med. 2019 Sep 30. doi: 10.1038/s41591-019-0582-4. [Epub ahead of print]
    • Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
    • Yu Y, Durairaj C, Shi H, Wang DD.
    • J Clin Pharmacol. 2019 Sep 6. doi: 10.1002/jcph.1520. [Epub ahead of print]
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    • Nuthalapati S, Stodtmann S, Shepherd SP, Ratajczak CK, Mensing S, Menon R, Xiong H.
    • Cancer Chemother Pharmacol. 2019 Aug 29. doi: 10.1007/s00280-019-03930-2. [Epub ahead of print]
    • A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    • Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P.
    • Sci Rep. 2019 Aug 29;9(1):12511. doi: 10.1038/s41598-019-48929-0.
    • Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    • Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worm H1, Moulder SL, Arun BK.
    • J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

    Research news: Study of the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising. (FORCE. XRAYS.)

    • A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents.
    • Xu K, Shi Y, Wang X, Chen Y, Tang L, Guan X.
    • Cancer Genet. 2019 Aug 23;239:26-32. doi: 10.1016/j.cancergen.2019.08.004. [Epub ahead of print]
    • Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
    • Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P.
    • Eur J Cancer. 2019 Aug 22;120:20-30. doi: 10.1016/j.ejca.2019.06.023. [Epub ahead of print]
    • EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.
    • Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat B.
    • Nanomedicine (Lond). 2019 Aug 21. doi: 10.2217/nnm-2019-0132. [Epub ahead of print]
    • Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
    • Boraei ATA, Singh PK, Sechi M, Satta S.
    • Eur J Med Chem. 2019 Aug 14;182:111621. doi: 10.1016/j.ejmech.2019.111621. [Epub ahead of print]
    • A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
    • Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT.
    • Theranostics. 2019 Aug 14;9(21):6224-6238. doi: 10.7150/thno.36281. eCollection 2019.
    • Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
    • Militello AM, Zielli T, Boggiani D, Michiara M, Naldi N, Bortesi B, Zanelli P, Uliana V, Giuliotti S, Musolino A.
    • Front Oncol. 2019 Aug 13;9:759. doi: 10.3389/fonc.2019.00759. eCollection 2019.
    • Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
    • West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE.
    • Cancer Med. 2019 Aug 12. doi: 10.1002/cam4.2471. [Epub ahead of print]
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Homologous recombination DNA repair defects in PALB2-associated breast cancers.
    • Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.
    • NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine.
    • Kerr DJ.
    • Medscape Oncology. 2019 Jul 18.

    Original research:

    Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.
    • Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, Leheurteur M, Demeestere I, Di Fiore F, Perdrix A, Clatot F.
    • Front Oncol. 2019 Jul 12;9:575. doi: 10.3389/fonc.2019.00575. eCollection 2019.
    • Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
    • Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.
    • Int J Mol Sci. 2019 Jul 10;20(14). pii: E3390. doi: 10.3390/ijms20143390.
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
    • Kim H, Lin Q, Yun Z.
    • Sci Rep. 2019 Jul 4;9(1):9702. doi: 10.1038/s41598-019-46210-y.
    • Evidence to date: talazoparib in the treatment of breast cancer.
    • Exman P, Barroso-Sousa R, Tolaney SM.
    • Onco Targets Ther. 2019 Jul 2;12:5177-5187. doi: 10.2147/OTT.S184971. eCollection 2019.
    • Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy.
    • Wang M, Huang J, Chagpar AB.
    • Am Surg. 2019 Jul 1;85(7):768-771.
    • Targeting DNA repair in breast cancer.
    • Paluch-Shimon S, Evron E.
    • Breast. 2019 Jul 1;47:33-42. doi: 10.1016/j.breast.2019.06.007. [Epub ahead of print]
    • Review
    • Talazoparib to treat BRCA-positive breast cancer.
    • Guney Eskiler G.
    • Drugs Today (Barc). 2019 Jul;55(7):459-467. doi: 10.1358/dot.2019.55.7.3015642.
    • Review
    • Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines.
    • Kundur S, Prayag A, Selvakumar P, Nguyen H, McKee L, Cruz C, Srinivasan A, Shoyele S, Lakshmikuttyamma A.
    • J Cell Physiol. 2019 Jul;234(7):11103-11118. doi: 10.1002/jcp.27761. Epub 2018 Nov 27.
    • Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.
    • Semushina SG, Aronov DA, Moiseeva EV.
    • Pathol Oncol Res. 2019 Jul;25(3):945-951. doi: 10.1007/s12253-018-0396-6. Epub 2018 Mar 6.
    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • A decade of clinical development of PARP inhibitors in perspective.
    • Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.
    • Ann Oncol. 2019 Jun 20. pii: mdz192. doi: 10.1093/annonc/mdz192. [Epub ahead of print]
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    • Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
    • Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.
    • Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.
    • Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    • Aktas BY, Guner G, Guven DC, Arslan C, Dizdar O.
    • Expert Rev Anticancer Ther. 2019 Jun 10. doi: 10.1080/14737140.2019.1631162. [Epub ahead of print]
    • Review
    • [Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.]
    • Palácová M.
    • Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.
    • [Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.]
    • Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
    • Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ.
    • Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • Therapeutic innovations in breast cancer.
    • Le Du F, Perrin C, Brunot A, Crouzet L, De La Motte Rouge T, Lefeuvre-Plesse C, Dieras V.
    • Presse Med. 2019 May 29. pii: S0755-4982(19)30165-4. doi: 10.1016/j.lpm.2019.04.005. [Epub ahead of print]
    • Review
    • Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
    • Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2019 May 24. pii: e9982. doi: 10.15252/emmm.201809982. [Epub ahead of print]
    • Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer.
    • Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32424. [Epub ahead of print]
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
    • Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.
    • Rev Med Suisse. 2019 May 15;15(651):1027-1031.
    • Review, [Article in French]
    • How I treat metastatic triple-negative breast cancer.
    • Caparica R, Lambertini M, de Azambuja E.
    • ESMO Open. 2019 May 13;4(Suppl 2):e000504. doi: 10.1136/esmoopen-2019-000504. eCollection 2019.
    • A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
    • Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group.
    • Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18.
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review
    • Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
    • Garber HR, Litton JK.
    • Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.
    • Review
    • [Genetic Approach of Breast Cancer].
    • Takei J, Yamauchi H.
    • Gan To Kagaku Ryoho. 2019 May;46(5):831-837.
    • Review, [Article in Japanese]
    • BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
    • EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.
    • Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips EH, Severson T, van de Ven M, Brambillasca CS, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler RK, Linn SC, Jonkers J.
    • Clin Cancer Res. 2019 Apr 29. pii: clincanres.4024.2018. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer.
    • Pantelidou C, Sonzogni O, de Oliveira Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.
    • Cancer Discov. 2019 Apr 23. pii: CD-18-1218. doi: 10.1158/2159-8290.CD-18-1218. [Epub ahead of print]
    • Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    • Ma X, Dang C, Min W, Diao Y, Hui W, Wang X, Dai Z, Wang X, Kang H.
    • Breast Cancer Res Treat. 2019 Apr 15. doi: 10.1007/s10549-019-05189-w. [Epub ahead of print]
    • Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
    • Na B, Yu X, Withers T, Gilleran J, Yao M, Foo TK, Chen C, Moore D, Lin Y, Kimball SD, Xia B, Ganesan S, Carpizo DR.
    • NPJ Breast Cancer. 2019 Apr 15;5:14. doi: 10.1038/s41523-019-0110-1. eCollection 2019.
    • β-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    • Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.
    • Carcinogenesis. 2019 Apr 9. pii: bgz070. doi: 10.1093/carcin/bgz070. [Epub ahead of print]
    • Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
    • Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ.
    • Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.
    • Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    • Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ.
    • Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
    • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    • Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM.
    • Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.
    • Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    • Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ, Noguchi S.
    • Breast Cancer Res Treat. 2019 Apr;174(3):627-637. doi: 10.1007/s10549-018-05120-9. Epub 2019 Jan 3.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
    • Force J, Leal JHS, McArthur HL.
    • Curr Treat Options Oncol. 2019 Mar 28;20(4):35. doi: 10.1007/s11864-019-0634-5.
    • Review
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
    • Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T.
    • Hered Cancer Clin Pract. 2019 Mar 25;17:11. doi: 10.1186/s13053-019-0111-y. eCollection 2019.
    • DNA polymerase θ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
    • Wang Z, Song Y, Li S, Kurian S, Xiang R, Chiba T, Wu X.
    • J Biol Chem. 2019 Mar 15;294(11):3909-3919. doi: 10.1074/jbc.RA118.005188. Epub 2019 Jan 17.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    • [No author given]
    • N Engl J Med. 2019 Mar 7;380(10):985-988. doi: 10.1056/NEJMc1900150.
    • Letter

    Original research:

    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

    • BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
    • Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, In Chan U, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX.
    • Hum Mol Genet. 2019 Mar 1;28(5):842-857. doi: 10.1093/hmg/ddy398.
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?
    • Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A.
    • Crit Rev Oncol Hematol. 2019 Mar;135:66-75. doi: 10.1016/j.critrevonc.2019.01.016. Epub 2019 Jan 30.
    • Review
    • A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    • Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.
    • Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.
    • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    • Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.
    • Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.
    • Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
    • Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J.
    • Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
    • Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
    • Caulfield SE, Davis CC, Byers KF.
    • J Adv Pract Oncol. 2019 Mar;10(2):167-174. Epub 2019 Mar 1.
    • Review
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    • Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C.
    • Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613. doi: 10.1073/pnas.1815126116. Epub 2019 Feb 7.
    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    • Murthy P, Muggia F.
    • Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    • Velázquez C, Esteban-Cardeñosa EM, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Durán M, Infante M.
    • Breast. 2019 Feb;43:91-96. doi: 10.1016/j.breast.2018.11.010. Epub 2018 Nov 29.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Treating metastatic breast cancer: Analysis of the impact of palbociclib (Ibrance) on overall survival in the PALOMA-3 trial.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 23.
    • Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    • Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J.
    • Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2.
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    • Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.
    • Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Improving outcomes for young women with breast cancer: fertility and childbearing issues.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 7.

    ClinicalTrials.gov: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) (NIH. ClinicalTrials.gov.)

    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    • Yap TA, Plummer R, Azad NS, Helleday T.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):185-195. doi: 10.1200/EDBK_238473.
    • Molecular Testing in Breast Cancer.
    • Litton JK, Burstein HJ, Turner NC.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):e1-e7. doi: 10.1200/EDBK_237715.
    • A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
    • Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y.
    • Cancer Med. 2019 Jan;8(1):383-399. doi: 10.1002/cam4.1892. Epub 2018 Dec 7.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
    • Fremd C, Jaeger D, Schneeweiss A.
    • Expert Rev Anticancer Ther. 2019 Jan;19(1):29-42. doi: 10.1080/14737140.2019.1537785. Epub 2018 Oct 29.
    • Review
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    • Li N, Wang Y, Deng W, Lin SH.
    • Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.
    • Review
    • PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing.
    • Schwartzberg L, Garber JE, Robson ME.
    • National Comprehensive Cancer Network. Continuing Education. 2018 Dec 30.
    • CEU Activity
    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    • Becker JR, Cuella-Martin R, Barazas M, Liu R, Oliveira C, Oliver AW, Bilham K, Holt AB, Blackford AN, Heierhorst J, Jonkers J, Rottenberg S, Chapman JR.
    • Nat Commun. 2018 Dec 17;9(1):5406. doi: 10.1038/s41467-018-07855-x.
    • Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
    • Nicolas E, Bertucci F, Sabatier R, Gonçalves A.
    • Cancers (Basel). 2018 Dec 11;10(12). pii: E506. doi: 10.3390/cancers10120506.
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • Emerging ways to treat breast cancer: will promises be met?
    • Samadi P, Saki S, Dermani FK, Pourjafar M, Saidijam M.
    • Cell Oncol (Dordr). 2018 Dec;41(6):605-621. doi: 10.1007/s13402-018-0409-1. Epub 2018 Sep 27.
    • Talazoparib: First Global Approval.
    • Hoy SM.
    • Drugs. 2018 Dec;78(18):1939-1946. doi: 10.1007/s40265-018-1026-z.
    • Review
    • [Systemic Treatment of Early and Metastatic Breast Cancer.]
    • Fehm T, Müller V.
    • Dtsch Med Wochenschr. 2018 Dec;143(24):1751-1754. doi: 10.1055/a-0638-4231. Epub 2018 Dec 3.
    • Review, [Article in German]
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy.
    • Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin LA, Gupta S, Mao G, Shekhar MP.
    • Mol Cancer Ther. 2018 Dec;17(12):2586-2597. doi: 10.1158/1535-7163.MCT-18-0364. Epub 2018 Sep 21.
    • Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
    • Guy H, Walder L, Fisher M.
    • Pharmacoeconomics. 2018 Nov 27. doi: 10.1007/s40273-018-0745-z. [Epub ahead of print]
    • Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    • Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S.
    • Bioconjug Chem. 2018 Nov 21;29(11):3817-3832. doi: 10.1021/acs.bioconjchem.8b00667. Epub 2018 Oct 25.
    • Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    • Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.
    • J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.

    Research news:

    Lurbinectedin for BRCA-mutated advanced breast cancer.

    Research news:

    Lurbinectedin Is Active in Patients with BRCA1/2 Mutant Breast Cancer.

    • Pricey Precision Medicine Often Financially Toxic For Cancer Patients.
    • Szabo L.
    • Kaiser Health News. 2018 Nov 1.

    Research News: The cost of cancer care and impact of financial hardship on treatment. (FORCE XRAYS)

    • PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    • Sharif-Askari B, Amrein L, Aloyz R, Panasci L.
    • Breast Cancer Res Treat. 2018 Nov;172(1):23-32. doi: 10.1007/s10549-018-4888-6. Epub 2018 Jul 23.
    • Mechanisms of PARP inhibitor sensitivity and resistance.
    • D'Andrea AD.
    • DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.
    • Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
    • Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM.
    • Eur J Cancer. 2018 Nov;104:160-168. doi: 10.1016/j.ejca.2018.09.003. Epub 2018 Oct 22.
    • Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy.
    • Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H, Sun M, Chai Z, Hou P, Geng X, Liu W, Wei M.
    • Oncol Lett. 2018 Nov;16(5):5621-5630. doi: 10.3892/ol.2018.9398. Epub 2018 Sep 5.
    • The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    • Sorscher S.
    • Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4.
    • Case report
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • FDA Approves Myriad's BRACAnalysis CDx for Use with Pfizer's Talzenna.
    • [No author given]
    • Clinical Omics. 2018 Oct 16.
    • FDA Approves PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2018 Oct 16.

    Original research:

    Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

    • Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (PROGECT).
    • Principal Investigator: Sharma P.
    • ClinicalTrials.gov. Last Update Posted: 2018 Oct 11. First Posted: 2014 Nov 27.
    • Genetic Markers in Triple-Negative Breast Cancer.
    • Sporikova Z, Koudelakova V, Trojanec R, Hajduch M.
    • Clin Breast Cancer. 2018 Oct;18(5):e841-e850. doi: 10.1016/j.clbc.2018.07.023. Epub 2018 Aug 4.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
    • Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.
    • J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.
    • Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
    • Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.
    • Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
    • Lurbinectedin for BRCA-mutated advanced breast cancer.
    • Gourd E.
    • Lancet Oncol. 2018 Sep 27. pii: S1470-2045(18)30737-X. doi: 10.1016/S1470-2045(18)30737-X. [Epub ahead of print]
    • Research news

    Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

    • Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • Pharm Res. 2018 Sep 25;35(11):218. doi: 10.1007/s11095-018-2502-6.
    • Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
    • Shen JP, Ideker T.
    • J Mol Biol. 2018 Sep 14;430(18 Pt A):2900-2912. doi: 10.1016/j.jmb.2018.06.026. Epub 2018 Jun 20.
    • Role of PARP Inhibitors in BRCA-Related Malignancies.
    • Iqbal S, Rattu MA, Shah N.
    • US Pharm. 2018 Sep 14;9(43):HS10-HS16
    • Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    • Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.
    • Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.
    • Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    • Yoshimura A, Okumura S, Sawaki M, Hattori M, Ishiguro J, Adachi Y, Kotani H, Gondo N, Kataoka A, Iwase M, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Takaiso N, Hyodo I, Iwata H.
    • Breast Cancer. 2018 Sep;25(5):539-546. doi: 10.1007/s12282-018-0850-z. Epub 2018 Mar 8.
    • Inherited gynaecological cancers.
    • George A.
    • Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.
    • Review
    • Emerging PARP inhibitors for treating breast cancer.
    • Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.
    • Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29.
    • Review
    • Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
    • Le D, Gelmon KA.
    • Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30.
    • Review
    • Resurrection of PARP Inhibitors in Breast Cancer.
    • Lyons TG, Robson ME.
    • J Natl Compr Canc Netw. 2018 Sep;16(9):1150-1156. doi: 10.6004/jnccn.2018.7031.
    • Review
    • Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    • Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.
    • N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

    Research news:

    Talazoparib for BRCA-mutated advanced breast cancer.

    Press: PARP Inhibitor Talazoparib Benefit in BCRA+ Breast Cancer. (Medscape Oncology)

    Press: FDA Approves PARP Inhibitor Talazoparib in BRCA+ Breast Cancer. (Medscape Oncology)

    • A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status.
    • Su YW, Hung CY, Lam HB, Chang YC, Yang PS.
    • Clin Med Insights Oncol. 2018 Aug 21;12:1179554918794672. doi: 10.1177/1179554918794672. eCollection 2018.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Advances in the use of PARP inhibitor therapy for breast cancer.
    • McCann KE, Hurvitz SA.
    • Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.
    • Tamoxifen withdrawal in women with progressive metastatic breast cancer: a case series of six patients.
    • Hagio K, Baba M, Ishida N, Oshino T, Kasahara R, Nara M, Yamashita H.
    • Int Cancer Conf J. 2018 Aug 6;7(4):142-147. doi: 10.1007/s13691-018-0339-9. eCollection 2018 Oct.
    • Case report
    • Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    • Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC.
    • Ann Oncol. 2018 Aug 1;29(8):1741-1747. doi: 10.1093/annonc/mdy209.
    • BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    • Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.
    • J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.
    • Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer.
    • Mehra NK, Tekmal RR, Palakurthi S.
    • Anticancer Res. 2018 Aug;38(8):4493-4503. doi: 10.21873/anticanres.12753.
    • Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.
    • Battisti NML, Okonji D, Manickavasagar T, Mohammed K, Allen M, Ring A.
    • Breast. 2018 Aug;40:60-66. doi: 10.1016/j.breast.2018.04.014. Epub 2018 Apr 23.
    • Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    • Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP.
    • Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22.
    • BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    • Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A.
    • Breast Cancer Res Treat. 2018 Aug;171(1):85-94. doi: 10.1007/s10549-018-4797-8. Epub 2018 May 3.
    • Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    • Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.
    • Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
    • Therapeutic landscape in mutational triple negative breast cancer.
    • Shi Y, Jin J, Ji W, Guan X.
    • Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.
    • Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
    • El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.
    • Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.
    • Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    • Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M.
    • Ann Oncol. 2018 Jul 1;29(7):1497-1508. doi: 10.1093/annonc/mdy127.
    • An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    • Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.
    • Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.
    • BRCA1/2 testing: therapeutic implications for breast cancer management.
    • Tung NM, Garber JE.
    • Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5.
    • Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    • Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.
    • Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.
    • Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    • Wang X, Shi Y, Huang D, Guan X.
    • Cancer Treat Rev. 2018 Jul;68:62-68. doi: 10.1016/j.ctrv.2018.05.014. Epub 2018 May 31.
    • Review
    • Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
    • Sulai NH, Tan AR.
    • Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501.
    • Responses to carboplatin in BRCA1/2-mutated breast cancer.
    • Burki TK.
    • Lancet Oncol. 2018 Jul;19(7):e337. doi: 10.1016/S1470-2045(18)30407-8. Epub 2018 May 24.
    • Research news
    • Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    • Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F.
    • Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.
    • A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer.
    • Wheelden M, Cream L, Sivik J, Robson M.
    • Case Rep Oncol Med. 2018 Jun 27;2018:9529821. doi: 10.1155/2018/9529821. eCollection 2018.
    • Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
    • Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C, Tagliamento M, Viglietti G, Del Mastro L, de Azambuja E, Lambertini M.
    • ESMO Open. 2018 Jun 20;3(4):e000361. doi: 10.1136/esmoopen-2018-000361. eCollection 2018.
    • Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
    • Novohradsky V, Zajac J, Vrana O, Kasparkova J, Brabec V.
    • Oncotarget. 2018 Jun 19;9(47):28456-28473. doi: 10.18632/oncotarget.25466. eCollection 2018 Jun 19.
    • PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    • Turk AA, Wisinski KB.
    • Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.
    • Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    • Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.
    • Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.
    • Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    • Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC.
    • Curr Oncol Rep. 2018 Jun 8;20(8):63. doi: 10.1007/s11912-018-0709-7.
    • Review
    • Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    • Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.
    • Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.
    • Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    • Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.
    • Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    • Papadimitriou M, Mountzios G, Papadimitriou CA.
    • Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.
    • Review
    • Advances in the systemic treatment of triple-negative breast cancer.
    • Lebert JM, Lester R, Powell E, Seal M, McCarthy J.
    • Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150. doi: 10.3747/co.25.3954. Epub 2018 Jun 13.
    • Olaparib for the treatment of breast cancer.
    • Griguolo G, Dieci MV, Guarneri V, Conte P.
    • Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30.
    • Review
    • Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    • Moore KN, Birrer MJ.
    • Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
    • Review
    • Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
    • Ruiz de Garibay G, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA.
    • Dis Model Mech. 2018 May 18;11(5). pii: dmm032292. doi: 10.1242/dmm.032292.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • New Treatment for BRCA-Mutated Metastatic Breast Cancer.
    • Aschenbrenner DS.
    • Am J Nurs. 2018 May;118(5):21-22. doi: 10.1097/01.NAJ.0000532827.55271.55.
    • Triple negative breast cancer: new therapeutic approaches and BRCA status.
    • Guney Eskiler G, Cecener G, Egeli U, Tunca B.
    • APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836.
    • Review
    • Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    • Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M.
    • Breast J. 2018 May;24(3):269-277. doi: 10.1111/tbj.12887. Epub 2017 Sep 19.
    • The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    • Domchek SM.
    • Clin Adv Hematol Oncol. 2018 May;16(5):330-332.

    • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts.
    • Untch M, Würstlein R, Marschner N, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Harbeck N, Thomssen C.
    • Geburtshilfe Frauenheilkd. 2018 May;78(5):469-480. doi: 10.1055/a-0594-2243. Epub 2018 Jun 4.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
    • Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J.
    • Hered Cancer Clin Pract. 2018 Apr 27;16:9. doi: 10.1186/s13053-018-0092-2. eCollection 2018.
    • Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    • Sharma P.
    • Curr Treat Options Oncol. 2018 Apr 14;19(5):22. doi: 10.1007/s11864-018-0539-8.
    • Review
    • Update on PARP Inhibitors in Breast Cancer.
    • Zimmer AS, Gillard M, Lipkowitz S, Lee JM.
    • Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2.
    • Review
    • Practical consensus recommendations on management of triple-negative metastatic breast cancer.
    • Rangarao R, Smruti BK, Singh K, Gupta A, Batra S, Choudhary RK, Gupta A, Sahani S, Kabra V, Parikh PM, Aggarwal S.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):127-131. doi: 10.4103/sajc.sajc_118_18.
    • Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
    • Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):156-158. doi: 10.4103/sajc.sajc_126_18.
    • Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    • Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.
    • Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.
    • Predictors of survival for breast cancer patients with a BRCA1 mutation.
    • Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, Szwiec M, Wisniowski R, Birkenfeld B, Kilar E, Sibilski R, Sun P, Lubinski J.
    • Breast Cancer Res Treat. 2018 Apr;168(2):513-521. doi: 10.1007/s10549-017-4605-x. Epub 2017 Dec 15.
    • Crosstalk of DNA double-strand break repair pathways in PARP inhibitor treatment of BRCA1/2-mutated Cancer.
    • Sunada S, Nakanishi A, Miki Y.
    • Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.
    • BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    • Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.
    • Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
    • PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    • Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.
    • Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4.
    • Review
    • [Molecular Targeted Therapies for Hereditary Cancer Syndrome].
    • Shimodaira H.
    • Gan To Kagaku Ryoho. 2018 Apr;45(4):587-592.
    • Review, [Article in Japanese]
    • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
    • Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
    • Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    • Tang YC, Ho SC, Tan E, Ng AWT, McPherson JR, Goh GYL, Teh BT, Bard F, Rozen SG.
    • Breast Cancer Res. 2018 Mar 22;20(1):22. doi: 10.1186/s13058-018-0949-3.
    • Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    • Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    • Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.
    • First PARP Inhibitor Approved for Breast Cancer.
    • [No authors listed]
    • Cancer Discov. 2018 Mar;8(3):256-257. doi: 10.1158/2159-8290.CD-NB2018-008. Epub 2018 Jan 30.
    • News
    • Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.
    • Sengodan SK, Sreelatha KH, Nadhan R, Srinivas P.
    • Crit Rev Oncol Hematol. 2018 Mar;123:74-82. doi: 10.1016/j.critrevonc.2018.01.008. Epub 2018 Feb 2.
    • Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
    • Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
    • Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.
    • A4 Results of cis-platinum treatment of breast cancer patients with brca1 mutation.
    • Narod S, Byrski T, Marczyk E, Wiśniowski R, Szwiec T, Huzarski T, Cybulski C, Dębniak T, Gronwald J, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A4. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A11 Similar 10-year survival in breast cancer with patients common BRCA1 mutations in Poland and Lithuania.
    • Elsakov P, Ostapenko V, Luksyte A, Smailyte G.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A11. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
    • Mylavarapu S, Das A, Roy M.
    • Front Oncol. 2018 Feb 5;8:16. doi: 10.3389/fonc.2018.00016. eCollection 2018.
    • "Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.
    • Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN.
    • Cureus. 2018 Feb 4;10(2):e2150. doi: 10.7759/cureus.2150.
    • Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    • Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.
    • Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Talazoparib Bests Chemo for Breast Cancer.
    • [No authors listed]
    • Cancer Discov. 2018 Feb;8(2):OF3. doi: 10.1158/2159-8290.CD-NB2017-180. Epub 2017 Dec 14.
    • Research news
    • Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    • Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.
    • Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
    • Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    • Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparano JA, Andreopoulou E.
    • Clin Breast Cancer. 2018 Feb;18(1):e135-e142. doi: 10.1016/j.clbc.2017.08.013. Epub 2017 Sep 1.
    • The development of PARP as a successful target for cancer therapy.
    • Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.
    • Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.
    • Review
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
    • Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martín M.
    • Clin Cancer Res. 2018 Jan 29. pii: clincanres.1912.2017. doi: 10.1158/1078-0432.CCR-17-1912. [Epub ahead of print]
    • Gene aberration profile of tumors of adolescent and young adult females.
    • Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
    • Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.
    • First Drug for BRCA Breast Cancer: Olaparib.
    • Chustecka Z.
    • Medscape. Medscape Medical News. 2018 Jan 12.

    Press: First treatment approved for breast cancer with BRCA genetic mutation. (Washington Post)

    • EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    • Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.
    • Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.
    • Rationale for Mastectomy after Neoadjuvant Chemotherapy.
    • Gusic LH, Walsh K, Flippo-Morton T, Sarantou T, Boselli D, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):126-132.
    • Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
    • Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.
    • Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

    Commentary:

    Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

    • Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
    • Privat M, Rudewicz J, Sonnier N, Tamisier C, Ponelle-Chachuat F, Bignon YJ.
    • Int J Med Sci. 2018 Jan 1;15(1):46-58. doi: 10.7150/ijms.20508. eCollection 2018.
    • Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    • Lee A, Djamgoz MBA.
    • Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017 Nov 13.
    • A Novel Model to Characterize Structure and Function of BRCA1.
    • Lin D, Izadpanah R, Braun SE, Alt E.
    • Cell Biol Int. 2018 Jan;42(1):34-44. doi: 10.1002/cbin.10846. Epub 2017 Oct 25.
    • Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.
    • Yeo SK, Paul R, Haas M, Wang C, Guan JL.
    • Autophagy. 2018;14(7):1214-1225. doi: 10.1080/15548627.2018.1460010. Epub 2018 Jul 20.
    • Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
    • Hjortkjær M, Kanstrup H, Jakobsen A, Steffensen KD.
    • Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review
    • BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    • Okuma HS, Yonemori K.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:271-286. doi: 10.1007/978-981-10-6020-5_13.
    • Review
    • Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.
    • Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM.
    • Oncotarget. 2017 Oct 31;8(67):111026-111040. doi: 10.18632/oncotarget.22195. eCollection 2017 Dec 19.
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.
    • Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.
    • NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.
    • Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
    • Zhang X, Hofmann S, Harbeck N, Jeschke U, Sixou S.
    • Drugs R D. 2017 Dec;17(4):569-583. doi: 10.1007/s40268-017-0208-6.
    • New agents for the management of resistant metastatic breast cancer.
    • Anampa J, Sparano JA.
    • Expert Opin Pharmacother. 2017 Dec;18(17):1815-1831. doi: 10.1080/14656566.2017.1409206. Epub 2017 Nov 27.
    • Review
    • PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    • Sisay M, Edessa D.
    • Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017.
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
    • Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.
    • Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.
    • Antitumor Activity of Copper (I)-Nicotinate Complex and Autophagy Modulation in HCC1806 Breast Cancer Cells.
    • Abdel-Mohsen MA, El-Shafey ES, Malak CA, Abou-Yossef MM.
    • Anticancer Agents Med Chem. 2017 Nov 24;17(11):1526-1536. doi: 10.2174/1871520617666170327144122.
    • The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    • Hromas R, Kim HS, Sidhu G, Williamson E, Jaiswal A, Totterdale TA, Nole J, Lee SH, Nickoloff JA, Kong KY./li>
    • Breast Cancer Res. 2017 Nov 16;19(1):122. doi: 10.1186/s13058-017-0912-8.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice.
    • Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P, Rottenberg S.
    • Clin Cancer Res. 2017 Nov 15;23(22):7020-7033. doi: 10.1158/1078-0432.CCR-17-1279. Epub 2017 Aug 18.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.
    • Castells M.
    • Front Immunol. 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. eCollection 2017.
    • Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    • Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L.
    • BMC Cancer. 2017 Nov 2;17(1):709. doi: 10.1186/s12885-017-3709-3.
    • Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors.
    • Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN.
    • Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8.
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    • Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J1, Reis-Filho JS, Greenberg RA, Robson M, Turner NC.
    • Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
    • Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment.
    • Ferrandina G, Amadio G, Marcellusi A, Azzolini E, Puggina A, Pastorino R, Ricciardi W, Scambia G.
    • Clin Drug Investig. 2017 Nov;37(11):1093-1102. doi: 10.1007/s40261-017-0571-7.
    • Doubling Down on BRCA-Mutated Cancer.
    • Wahner Hendrickson AE, Kaufmann SH, Swisher EM.
    • Trends Cancer. 2017 Nov;3(11):743-744. doi: 10.1016/j.trecan.2017.09.005. Epub 2017 Sep 29.
    • Review
    • A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
    • Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J.
    • Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.
    • Role of PARP Inhibitors in Triple-Negative Breast Cancer.
    • Azvolinsky A, Garber J.
    • OncoTherapy Network. 2017 Oct 4.
    • Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    • Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.
    • JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.

    Editorial:

    Use of Neoadjuvant Platinum-The Ongoing Conundrum.

    • BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    • Paculová H, Kramara J, Šimečková Š, Fedr R, Souček K, Hylse O, Paruch K, Svoboda M, Mistrík M, Kohoutek J.
    • Tumour Biol. 2017 Oct;39(10):1010428317727479. doi: 10.1177/1010428317727479.
    • The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
    • Strumidło A, Skiba S, Scott RJ, Lubiński J.
    • Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.
    • Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.
    • Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S.
    • Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017.
    • Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
    • Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.
    • Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
    • More breast cancer patients could benefit from PARP inhibitors.
    • [No author given]
    • Cancer. 2017 Sep 15;123(18):3433. doi: 10.1002/cncr.30962.
    • Research news
    • Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1.
    • Qin T, Huang G, Chi L, Sui S, Song C, Li N, Sun S, Li N, Zhang M, Zhao Z, Li L, Li M.
    • Biomed Pharmacother. 2017 Sep 4;95:649-655. doi: 10.1016/j.biopha.2017.08.095. [Epub ahead of print]
    • Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.
    • Sorscher S.
    • JAMA Oncol. 2017 Sep 1;3(9):1283-1284. doi: 10.1001/jamaoncol.2017.0659.
    • Letter, Comment

    Review:

    The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
    • Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K.
    • Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    • Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.
    • Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.
    • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.
    • N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.

    Letter:

    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

    Press: Olaparib: New Standard for BRCA-Mutated Breast Cancer? (Medscape)

    • H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
    • Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F.
    • Sci Rep. 2017 Aug 8;7(1):7505. doi: 10.1038/s41598-017-07617-7.
    • Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    • Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H, Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN.
    • Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.
    • Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
    • Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J.
    • Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30.
    • Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    • Harbeck N, Gluz O.
    • Breast. 2017 Aug;34 Suppl 1:S99-S103. doi: 10.1016/j.breast.2017.06.038. Epub 2017 Jun 27.
    • Review
    • Olaparib Keeps Hereditary Breast Tumors in Check.
    • [No authors listed]
    • Cancer Discov. 2017 Aug;7(8):OF10. doi: 10.1158/2159-8290.CD-NB2017-085. Epub 2017 Jun 5.
    • Research news
    • A novel Ubc9 -dependent pathway regulates SIRT1- ER-α Axis and BRCA1-associated TNBC lung metastasis.
    • Xu J, Shumate C, Qin Y, Reddy V, Burnam Y, Lopez V, Okoli J, P Reddy ES, Rao VN.
    • Integr Mol Med. 2017 Aug;4(4). doi: 10.15761/IMM.1000298. Epub 2017 Jul 28.
    • Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
    • Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.
    • Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.
    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    • Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.
    • Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
    • Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report.
    • Saha D, Tannenbaum S, Zhu Q.
    • Cureus. 2017 Jul 17;9(7):e1481. doi: 10.7759/cureus.1481.
    • Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    • Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.
    • JAMA Oncol. 2017 Jul 13. doi: 10.1001/jamaoncol.2017.1007. [Epub ahead of print]
    • Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.
    • Dosani M, Schrader KA, Nichol A, Sun S, Shenkier T, Lohn Z, Aubertin G, Tyldesley S.
    • Cureus. 2017 Jul 11;9(7):e1458. doi: 10.7759/cureus.1458.
    • Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding.
    • Irmejs A, Loza P, Skuja E, Gardovskis J.
    • Cureus. 2017 Jul 10;9(7):e1455. doi: 10.7759/cureus.1455.
    • Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    • Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann EA, Hartman AR, Ford JM, Telli ML.
    • Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.
    • Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer.
    • Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa A, Goldenberg DM.
    • Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.
    • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.
    • J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.
    • Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.
    • Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322.
    • Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    • Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.
    • Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.
    • Identification of BRCA1 As a Potential Biomarker for Insulin-Like Growth Factor-1 Receptor Targeted Therapy in Breast Cancer.
    • Cohen-Sinai T, Cohen Z, Werner H, Berger R.
    • Front Endocrinol (Lausanne). 2017 Jun 29;8:148. doi: 10.3389/fendo.2017.00148. eCollection 2017.
    • Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    • Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF; SOFT; TEXT Investigators; International Breast Cancer Study Group.
    • J Clin Oncol. 2017 Jun 27:JCO2016720946. doi: 10.1200/JCO.2016.72.0946. [Epub ahead of print]
    • Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
    • Denkert C, Liedtke C, Tutt A, von Minckwitz G.
    • Lancet. 2017 Jun 17;389(10087):2430-2442. doi: 10.1016/S0140-6736(16)32454-0. Epub 2016 Dec 7.
    • Review
    • Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.
    • de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB.
    • Oncotarget. 2017 Jun 15;8(37):60750-60763. doi: 10.18632/oncotarget.18490. eCollection 2017 Sep 22.
    • OlympiAD: Olaparib Captures Gold for BRCA-Mutated Breast Cancer Patients.
    • Miller KD, Domchek SM.
    • Medscape. Coverage from the ASCO 2017 Annual Meeting. 2017 Jun 12.
    • Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib.
    • Rizvi W, Truong P, Truong Q.
    • Cureus. 2017 Jun 11;9(6):e1337. doi: 10.7759/cureus.1337.
    • Olaparib provides benefit in metastatic breast cancer.
    • Das M
    • Lancet Oncol. 2017 Jun 8. doi: 10.1016/S1470-2045(17)30453-9. [Epub ahead of print]
    • Olaparib Keeps Hereditary Breast Tumors in Check.
    • [No authors listed]
    • Cancer Discov. 2017 Jun 5. doi: 10.1158/2159-8290.CD-NB2017-085. [Epub ahead of print]
    • Research news
    • Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
    • Cuyàs E, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    • Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Niraparib: First Global Approval.
    • Scott LJ.
    • Drugs. 2017 Jun;77(9):1029-1034. doi: 10.1007/s40265-017-0752-y.
    • Review
    • Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    • Talens F, Jalving M, Gietema JA, van Vugt MATM.
    • Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.
    • Olaparib for the treatment of breast cancer.
    • Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.
    • Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.
    • Review
    • Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    • Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.
    • J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.
    • Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.
    • Parkes A, Arun BK, Litton JK.
    • Oncologist. 2017 Jun;22(6):655-666. doi: 10.1634/theoncologist.2016-0430. Epub 2017 May 3.
    • Review
    • Two 'P' Words Top List of Hot Topics in Breast Cancer.
    • Miller KD.
    • Medscape. Coverage from the ASCO 2017 Annual Meeting. 2017 May 26.
    • Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
    • Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):65-77. doi: 10.1200/EDBK_200715.
    • BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
    • Cuyàs E, Corominas-Faja B, Muñoz-San Martín M, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.
    • Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.
    • Current perspectives on CHEK2 mutations in breast cancer.
    • Apostolou P, Papasotiriou I.
    • Breast Cancer (Dove Med Press). 2017 May 12;9:331-335. doi: 10.2147/BCTT.S111394. eCollection 2017.
    • Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation.
    • Galvão VR, Phillips E, Giavina-Bianchi P, Castells MC.
    • J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):816-818. doi: 10.1016/j.jaip.2016.08.012. Epub 2016 Oct 17.
    • Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    • El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C.
    • Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.
    • Chen F, Pu F.
    • Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017.
    • BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    • Domagala P, Hybiak J, Cybulski C, Lubinski J.
    • Int J Cancer. 2017 Apr 1;140(7):1545-1550. doi: 10.1002/ijc.30570. Epub 2017 Jan 24.
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.
    • Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
    • A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
    • Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.
    • Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.
    • The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
    • Castrellon AB, Pidhorecky I, Valero V, Raez LE.
    • Oncol Rev. 2017 Mar 17;11(1):324. doi: 10.4081/oncol.2017.324. eCollection 2017.
    • Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.
    • Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    • Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.
    • Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.
    • Investigational drug combined with chemotherapy improves response in patients with BRCA-mutant breast cancer.
    • Printz C.
    • Cancer. 2017 Mar 1;123(5):722-723. doi: 10.1002/cncr.30610.
    • Research news
    • BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.
    • Lips EH, Debipersad R, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.
    • Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.
    • [Fullerene Doxorubicin Nanotransporter for Target Interaction with mutated gene BRCA2].
    • Skaličková S, Löfelmann M, Gargulák M, Dočekalová M, Ruttkay-Nedecký B, Suchý P, Kepinská M, Kizek R.
    • Klin Onkol. 2017 Spring;30(Supplementum1):177-179.
    • Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    • Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.
    • Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.
    • PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    • Song W, Tang L, Xu Y, Xu J, Zhang W, Xie H, Wang S, Guan X.
    • Sci Rep. 2017 Feb 8;7:42319. doi: 10.1038/srep42319.
    • An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity.
    • Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Md RI.
    • Genes (Basel). 2017 Feb 2;8(2). pii: E59. doi: 10.3390/genes8020059.
    • Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
    • Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner J, Mammen JM, McGinness M, Klemp JR, Amin A, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.
    • Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.
    • The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.
    • Niravath P, Cakar B, Ellis M.
    • JAMA Oncol. 2017 Feb 1;3(2):262-268. doi: 10.1001/jamaoncol.2016.2719.
    • Review

    Letter, Comment:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
    • Pearson EJ, Nair A, Daoud Y, Blum JL.
    • Breast Cancer Res Treat. 2017 Feb;162(1):59-67. doi: 10.1007/s10549-016-4101-8. Epub 2017 Jan 9./cite>
    • Integrating genomic information and signaling dynamics for efficient cancer therapy.
    • Stewart-Ornstein J, Lahav G.
    • Curr Opin Syst Biol. 2017 Feb;1:38-43. doi: 10.1016/j.coisb.2016.12.013. Epub 2016 Dec 19.
    • A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
    • Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP.
    • Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.
    • DNA damage repair in breast cancer and its therapeutic implications.
    • Ali R, Rakha EA, Madhusudan S, Bryant HE.
    • Pathology. 2017 Feb;49(2):156-165. doi: 10.1016/j.pathol.2016.11.002. Epub 2016 Dec 26.
    • Review
    • Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function.
    • Mgbemena VE, Signer RA, Wijayatunge R, Laxson T, Morrison SJ, Ross TS.
    • Cell Rep. 2017 Jan 24;18(4):947-960. doi: 10.1016/j.celrep.2016.12.075.
    • RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    • Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S.
    • Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.
    • The fate of BRCA1-related germline mutations in triple-negative breast tumors.
    • Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.
    • Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.
    • Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
    • Ratanaphan A, Nhukeaw T, Hongthong K, Dyson PJ.
    • Anticancer Agents Med Chem. 2017;17(2):212-220.
    • MicroRNA in breast cancer: The association with BRCA1/2.
    • Nina P, Radoslav D, Vladan B, Milan O, Esma IR.
    • Cancer Biomark. 2017;19(2):119-128. doi: 10.3233/CBM-160319.
    • Review
    • Fork Protection and Therapy Resistance in Hereditary Breast Cancer.
    • Cantor SB, Calvo JA.
    • Cold Spring Harb Symp Quant Biol. 2017;82:339-348. doi: 10.1101/sqb.2017.82.034413. Epub 2018 Feb 22.
    • ASCO 2017: highlights in breast cancer.
    • Bartsch R, Bergen E.
    • Memo. 2017;10(4):228-232. doi: 10.1007/s12254-017-0368-7. Epub 2017 Nov 13.
    • SABCS 2016: systemic therapy for metastatic breast cancer.
    • Gampenrieder SP, Rinnerthaler G, Greil R.
    • Memo. 2017;10(2):86-89. doi: 10.1007/s12254-017-0326-4. Epub 2017 Apr 4.
    • Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
    • Liedtke C, Rody A.
    • Rev Recent Clin Trials. 2017;12(2):73-80. doi: 10.2174/1574887112666170307095945.
    • Review
    • Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor Olaparib by a dominant negative effect.
    • Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro AN, Benítez J, Osorio A.
    • Hum Mol Genet. 2016 Dec 15;25(24):5287-5299. doi: 10.1093/hmg/ddw343.
    • BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.
    • PLoS One. 2016 Dec 9;11(12):e0165721. doi: 10.1371/journal.pone.0165721. eCollection 2016.
    • miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
    • Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.
    • Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.
    • The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    • Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, Xu J, Guan X.
    • Int J Biol Sci. 2016 Nov 25;12(12):1500-1510. eCollection 2016.
    • CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    • Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.
    • Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.
    • FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
    • Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y, Zhang X, Bagaria S, Taylor C, Giuliano AE, Amersi F, Cui X.
    • Oncotarget. 2016 Nov 15;7(46):75729-75738. doi: 10.18632/oncotarget.12370.
    • The BROCADE 3 Study.
    • Shannon Puhalla.
    • FORCE. Be Empowered Webinars. 2016 Nov 14.
    • The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
    • Bhute VJ, Ma Y, Bao X, Palecek SP.
    • Sci Rep. 2016 Nov 4;6:36061. doi: 10.1038/srep36061.
    • Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    • Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    • Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.
    • Review
    • Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    • Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J.
    • Oncotarget. 2016 Oct 18;7(42):68662-68673. doi: 10.18632/oncotarget.11900.
    • Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    • Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV.
    • Cancer Cell. 2016 Oct 10;30(4):637-650. doi: 10.1016/j.ccell.2016.09.002.
    • RING-less BRCA1 Induces PARP Inhibitor and Platinum Resistance.
    • [No authors listed]
    • Cancer Discov. 2016 Oct;6(10):OF6. Epub 2016 Aug 12.
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Synthetic lethality: the road to novel therapies for breast cancer.
    • Dhillon KK, Bajrami I, Taniguchi T, Lord C.
    • Endocr Relat Cancer. 2016 Oct;23(10):T39-T55. Epub 2016 Aug 15.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
    • Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D.
    • Future Oncol. 2016 Oct;12(19):2189-93. doi: 10.2217/fon-2016-0116. Epub 2016 Jun 21.
    • Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer.
    • Hsieh AH, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B.
    • Intern Med J. 2016 Oct;46(10):1153-1159. doi: 10.1111/imj.13169.
    • Breast cancer in BRCA mutation carriers: medical treatment.
    • Milani A, Geuna E, Zucchini G, Aversa C, Martinello R, Montemurro F.
    • Minerva Ginecol. 2016 Oct;68(5):557-65. Epub 2016 Jan 22.
    • Review
    • Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2016 Sep 23. pii: clincanres.1546.2016. [Epub ahead of print]
    • 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    • Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B.
    • BMC Cancer. 2016 Sep 9;16(1):725. doi: 10.1186/s12885-016-2754-7.
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • PTIP Loss Protects BRCA-Deficient Cells from DNA Damage and Cell Death.
    • [No authors listed]
    • Cancer Discov. 2016 Sep;6(9):944. doi: 10.1158/2159-8290.CD-RW2016-142. Epub 2016 Jul 29.
    • Research Watch
    • PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    • Crafton SM, Bixel K, Hays JL.
    • Gynecol Oncol. 2016 Sep;142(3):588-96. doi: 10.1016/j.ygyno.2016.05.003. Epub 2016 Jul 25.
    • Review
    • Cytotoxic and targeted therapy for hereditary cancers.
    • Iyevleva AG, Imyanitov EN.
    • Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016.
    • BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
    • Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.
    • Int J Cancer. 2016 Aug 15;139(4):882-889. doi: 10.1002/ijc.30078. Epub 2016 May 5.
    • Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer.
    • Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.
    • Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.
    • BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    • Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.
    • J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    • Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.
    • J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25.

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
    • Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.
    • Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4.
    • News on the medical treatment of young women with early-stage HER2-negative breast cancer.
    • Lambertini M, Poggio F, Vaglica M, Blondeaux E, Del Mastro L.
    • Expert Opin Pharmacother. 2016 Aug;17(12):1643-55. doi: 10.1080/14656566.2016.1199685. Epub 2016 Jun 20.
    • Review
    • Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
    • Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17.
    • Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
    • Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM.
    • Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8.
    • Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    • Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Jóźwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.
    • J Natl Cancer Inst. 2016 Jul 5;108(11). pii: djw148. Print 2016 Nov.
    • PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
    • Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V.
    • Cancer Cell Int. 2016 Jul 1;16:53. doi: 10.1186/s12935-016-0333-2. eCollection 2016.
    • Do platinum salts fit all triple negative breast cancers?
    • Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F.
    • Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11.
    • Review
    • BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    • Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    • Eur J Surg Oncol. 2016 Jul;42(7):999-1001. doi: 10.1016/j.ejso.2016.02.246. Epub 2016 Mar 2.
    • Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
    • Goyal G, Fan T, Silberstein PT.
    • Fam Cancer. 2016 Jul;15(3):359-66. doi: 10.1007/s10689-016-9883-7.
    • A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    • Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC.
    • Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.
    • BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.
    • Gu Y, Helenius M, Väänänen K, Bulanova D, Saarela J, Sokolenko A, Martens J, Imyanitov E, Kuznetsov S.
    • Sci Rep. 2016 Jun 17;6:28217. doi: 10.1038/srep28217.
    • Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.
    • Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S.
    • Cancers (Basel). 2016 Jun 16;8(6). pii: E56. doi: 10.3390/cancers8060056.
    • Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    • Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.
    • PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
    • Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    • Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.
    • Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.
    • Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
    • Li M, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Gene. 2016 Jun 10;584(1):26-30. doi: 10.1016/j.gene.2016.03.004. Epub 2016 Mar 5.
    • Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
    • Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH.
    • Invest New Drugs. 2016 Jun;34(3):355-63. doi: 10.1007/s10637-016-0335-x. Epub 2016 Mar 21.
    • Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
    • Nair RS, Kumar JM, Jose J, Somasundaram V, Hemalatha SK, Sengodan SK, Nadhan R, Anilkumar TV, Srinivas P.
    • Sci Rep. 2016 May 25;6:26631. doi: 10.1038/srep26631.
    • Triple-negative breast cancer: treatment challenges and solutions.
    • Collignon J, Lousberg L, Schroeder H, Jerusalem G.
    • Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.
    • The OlympiA Trial.
    • Charles E. Geyer.
    • FORCE. Be Empowered Webinars. 2016 May 3.
    • Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    • Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.
    • Biochem Pharmacol. 2016 May 1;107:29-40. doi: 10.1016/j.bcp.2016.02.015. Epub 2016 Feb 24.
    • Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
    • Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B.
    • Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25.
    • Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    • Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.
    • Cancer. 2016 Apr 15;122(8):1178-1184. doi: 10.1002/cncr.29903. Epub 2016 Feb 9.
    • A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
    • Buckley NE, Haddock P, De Matos Simoes R, Parkes E, Irwin G, Emmert-Streib F, McQuaid S, Kennedy R, Mullan P.
    • Oncotarget. 2016 Apr 12;7(15):19884-96. doi: 10.18632/oncotarget.7865.
    • Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine.
    • Nilov DK, Tararov VI, Kulikov AV, Zakharenko AL, Gushchina IV, Mikhailov SN, Lavrik OI, Švedas VK.
    • Acta Naturae. 2016 Apr-Jun;8(2):108-15.
    • Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
    • Drooger JC, Heemskerk-Gerritsen BA, Smallenbroek N, Epskamp C, Seynaeve CM, Jager A.
    • Breast Cancer Res Treat. 2016 Apr;156(3):557-66. doi: 10.1007/s10549-016-3777-0. Epub 2016 Apr 9.
    • Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
    • Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.
    • Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22.
    • [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
    • Zhang J, Sun J, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT.
    • Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):185-9. doi: 10.3760/cma.j.issn.0253-3766.2016.03.005.
    • Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    • Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P.
    • BMC Cancer. 2016 Mar 15;16(1):219. doi: 10.1186/s12885-016-2261-x.
    • Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    • Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).
    • Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.
    • Genetics of triple-negative breast cancer: Implications for patient care.
    • Afghahi A, Telli ML, Kurian AW.
    • Curr Probl Cancer. 2016 Mar - Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23.
    • Review
    • Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.
    • Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD.
    • AAPS J. 2016 Mar;18(2):362-71. doi: 10.1208/s12248-015-9838-1. Epub 2015 Nov 24.
    • Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    • Jia LY, Shanmugam MK, Sethi G, Bishayee A.
    • Anticancer Drugs. 2016 Mar;27(3):147-55. doi: 10.1097/CAD.0000000000000328.
    • Review
    • Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.
    • Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J.
    • J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710.
    • Case report
    • Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis.
    • De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.
    • Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.
    • Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    • Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.
    • Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367.
    • Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    • Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M.
    • Oncotarget. 2016 Feb 16;7(7):7701-14. doi: 10.18632/oncotarget.6715.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
    • Manié E, Popova T, Battistella A, Tarabeux J, Caux-Moncoutier V, Golmard L, Smith NK, Mueller CR, Mariani O, Sigal-Zafrani B, Dubois T, Vincent-Salomon A, Houdayer C, Stoppa-Lyonnet D, Stern MH.
    • Int J Cancer. 2016 Feb 15;138(4):891-900. doi: 10.1002/ijc.29829. Epub 2015 Sep 24.
    • Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
    • Zimmer J, Tacconi EM, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.
    • Mol Cell. 2016 Feb 4;61(3):449-60. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.
    • Patterns in target-directed breast cancer research.
    • Torres S, Simmons C, Boileau JF, McLeod D, Martins I, Trudeau M.
    • Springerplus. 2016 Feb 1;5:109. doi: 10.1186/s40064-016-1736-1. eCollection 2016.
    • Triple-negative breast cancer: advancements in characterization and treatment approach.
    • Hurvitz S, Mead M.
    • Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239.
    • Review
    • [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
    • Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, Hou C, Lee H, Greenberg RA, Mankoff DA, Mach RH.
    • Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):94-101. eCollection 2016.
    • Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    • Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA.
    • Cancer. 2016 Jan 15;122(2):304-311. doi: 10.1002/cncr.29615. Epub 2015 Dec 7.

    Editorial / Commentary

    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ATM heterozygotes and radiation

    • A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin.
    • Hamad L, Khoury T, Vona K, Nestico J, Opyrchal M, Salerno KE.
    • Cureus. 2016 Jan 11;8(1):e454. doi: 10.7759/cureus.454.
    • Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.
    • Partipilo G, Simone G, Scattone A, Scarpi E, Azzariti A, Mangia A.
    • Int J Cancer. 2016 Jan 1;138(1):110-20. doi: 10.1002/ijc.29699. Epub 2015 Aug 6.
    • Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
    • Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA, Swain SM, Warren R, Peshkin BN, Isaacs C.
    • Breast Cancer Res Treat. 2016 Jan;155(2):285-93. doi: 10.1007/s10549-016-3678-2. Epub 2016 Jan 9.
    • Trabectedin for the treatment of breast cancer.
    • D'Incalci M, Zambelli A.
    • Expert Opin Investig Drugs. 2016 Jan;25(1):105-15. doi: 10.1517/13543784.2016.1124086. Epub 2015 Dec 22.
    • Review
    • High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
    • Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC.
    • Mol Cancer Ther. 2016 Jan;15(1):190-8. doi: 10.1158/1535-7163.MCT-15-0470. Epub 2015 Dec 4.
    • Pharmacogenetic Predictors of Response.
    • Hertz DL, Rae JM.
    • Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6_8.
    • Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain.
    • Koumarianou A, Kontopoulou C, Kouloulias V, Tsionou C.
    • Case Rep Oncol Med. 2016;2016:5718104. doi: 10.1155/2016/5718104. Epub 2016 Apr 18.
    • BRCA1-associated triple-negative breast cancer and potential treatment for ruthenium-based compounds.
    • Hongthong K, Ratanaphan A.
    • Curr Cancer Drug Targets. 2016;16(7):606-17.
    • Review
    • [Specific features of drug sensitivity of hereditary cancers].
    • Imyanitov EN.
    • Vopr Onkol. 2016;62(2):221-6.
    • Review, [Article in Russian]
    • Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
    • Steenbruggen TG, Linn SC, Rodenhuis S, Sonke GS.
    • Cureus. 2015 Dec 24;7(12):e433. doi: 10.7759/cureus.433.
    • Targeting tumor suppressor genes for cancer therapy.
    • Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X.
    • Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7.
    • Review
    • Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    • Węsierska-Gądek J, Mauritz M, Mitulovic G, Cupo M.
    • J Cell Biochem. 2015 Dec;116(12):2824-39. doi: 10.1002/jcb.25229.
    • Breast Cancer, Version 1.2016.
    • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.
    • Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
    • Choi YE, Park E.
    • J Nutr Biochem. 2015 Dec;26(12):1442-7. doi: 10.1016/j.jnutbio.2015.07.015. Epub 2015 Aug 8.
    • Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.
    • Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, Helbich TH.
    • Wien Klin Wochenschr. 2015 Dec;127(23-24):981-6. doi: 10.1007/s00508-015-0880-x. Epub 2015 Nov 2.
    • Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.
    • Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.
    • Chem Biol. 2015 Nov 19;22(11):1491-504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.
    • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
    • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.
    • N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

    Comment / Editorial

    Biology before Anatomy in Early Breast Cancer--Precisely the Point.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Press: Breast Cancer Gene Test Helps Predict Who Can Skip Chemo (NPR)

    • First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
    • Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A.
    • Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
    • Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.
    • Stover DG, Winer EP.
    • Breast. 2015 Nov;24 Suppl 2:S132-5. doi: 10.1016/j.breast.2015.07.032. Epub 2015 Aug 5.
    • SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
    • Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.
    • Breast Cancer Res Treat. 2015 Nov;154(2):351-357. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.
    • Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
    • OʼSullivan Coyne G, Chen A, Kummar S.
    • Curr Opin Oncol. 2015 Nov;27(6):475-81. doi: 10.1097/CCO.0000000000000238.
    • Review
    • Successes and Challenges of PARP Inhibitors in Cancer Therapy.
    • Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.
    • Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015.
    • Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
    • Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.
    • Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.
    • BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
    • Kan C, Zhang J.
    • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.
    • Review
    • [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    • Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    • Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
    • Review, [Article in French]
    • Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    • Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.
    • Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.
    • Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    • Kriege M, Jager A, Hollestelle A, Berns EM, Blom J, Meijer-van Gelder ME, Sieuwerts AM, van den Ouweland A, Collée JM, Kroep JR, Martens JW, Hooning MJ, Seynaeve C.
    • J Cancer Res Clin Oncol. 2015 Oct;141(10):1879-87. doi: 10.1007/s00432-015-1981-7. Epub 2015 May 10.
    • BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    • Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.
    • Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.
    • The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy.
    • Aiad HA, Kandil MA, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA, Aleskandarany MA.
    • Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):571-9. doi: 10.1097/PAI.0000000000000124.
    • Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    • Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP.
    • Breast Cancer Res Treat. 2015 Sep;153(2):435-43. doi: 10.1007/s10549-015-3545-6. Epub 2015 Aug 22.
    • A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    • Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.
    • Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
    • PARP inhibitors in the management of breast cancer: current data and future prospects.
    • Livraghi L, Garber JE.
    • BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1.
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
    • Copur MS, Gauchan D, Brussow K, Clark D, Ramaekers R.
    • J Clin Oncol. 2015 Aug 10;33(23):2582. doi: 10.1200/JCO.2015.61.0576. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
    • Miquel-Cases A, Steuten LM, Retèl VP, van Harten WH.
    • Breast. 2015 Aug;24(4):397-405. doi: 10.1016/j.breast.2015.03.002. Epub 2015 Apr 28.
    • Molecular aspects of breast cancer resistance to drugs (Review).
    • Calaf GM, Zepeda AB, Castillo RL, Figueroa CA, Arias C, Figueroa E, Farías JG.
    • Int J Oncol. 2015 Aug;47(2):437-45. doi: 10.3892/ijo.2015.3055. Epub 2015 Jun 18.
    • Review
    • Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.
    • Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.
    • Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.
    • Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
    • van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.
    • Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.
    • Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
    • Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP, de Korte-Grimmerink R, Gogola E, Szuhai K, Schlicker A, Bin Ali R, Pritchard C, Huijbers IJ, Berns A, Rottenberg S, Jonkers J.
    • Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8409-14. doi: 10.1073/pnas.1500223112. Epub 2015 Jun 22.
    • Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.
    • Yi YW, Park JS, Kwak SJ, Seong YS.
    • Anticancer Res. 2015 Jul;35(7):3829-38.
    • The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    • Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.
    • Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.
    • Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.
    • Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.
    • Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.
    • Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
    • Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM.
    • J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.
    • TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    • Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.
    • J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.
    • Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
    • Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.
    • Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.
    • The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
    • Li M, Yu X.
    • Oncogene. 2015 Jun;34(26):3349-56. doi: 10.1038/onc.2014.295. Epub 2014 Sep 15.
    • Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
    • Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.
    • Oncotarget. 2015 May 10;6(13):11575-84.
    • Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    • Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.
    • Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.
    • Therapies for triple negative breast cancer.
    • Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.
    • Expert Opin Pharmacother. 2015 May;16(7):983-98.
    • Review
    • Triple Negative Breast Cancer in BRCA1 Mutation Carriers With a Complete Radiologic Response to Neoadjuvant Paclitaxel: A Case Report.
    • Burness ML, Obeid EI, Olopade OI.
    • Clin Breast Cancer. 2015 Apr;15(2):e155-8. doi: 10.1016/j.clbc.2014.08.006. Epub 2014 Sep 28.
    • Case report
    • High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation.
    • Moiseyenko VM, Dolmatov GD, Moiseyenko FV, Ivantsov AO, Volkov NM, Chubenko VA, Abduloeva NKh, Bogdanov AA, Sokolenko AP, Imyanitov EN.
    • Med Oncol. 2015 Apr;32(4):514. doi: 10.1007/s12032-015-0514-1. Epub 2015 Feb 25.
    • Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    • Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK.
    • Mol Cancer Ther. 2015 Apr;14(4):920-30. doi: 10.1158/1535-7163.MCT-14-0474.
    • Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    • Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • BMC Cancer. 2015 Mar 28;15:194. doi: 10.1186/s12885-015-1203-3.
    • Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    • Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.
    • PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.
    • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    • Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    • Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.
    • Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    • Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    • BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.
    • Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
    • Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Ann Oncol. 2015 Mar;26(3):523-8. doi: 10.1093/annonc/mdu559. Epub 2014 Dec 5.
    • [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].
    • Clergue O, Jones N, Sévenet N, Quenel-Tueux N, Debled M.
    • Bull Cancer. 2015 Mar;102(3):245-55. doi: 10.1016/j.bulcan.2015.01.010. Epub 2015 Mar 7.
    • Review, [Article in French]
    • An update on PARP inhibitors for the treatment of cancer.
    • Benafif S, Hall M.
    • Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
    • BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
    • Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.
    • Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.
    • Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy.
    • Schouten PC, Marmé F, Aulmann S, Sinn HP, van Essen HF, Ylstra B, Hauptmann M, Schneeweiss A, Linn SC.
    • Clin Cancer Res. 2015 Feb 15;21(4):763-70. doi: 10.1158/1078-0432.CCR-14-1894. Epub 2014 Dec 5.
    • Familial breast cancer - targeted therapy in secondary and tertiary prevention.
    • Kast K, Rhiem K.
    • Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756.
    • BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    • Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.
    • Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.
    • Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    • Jacot W, Theillet C, Guiu S, Lamy PJ.
    • Future Oncol. 2015 Feb;11(4):557-9. doi: 10.2217/fon.14.268.
    • Letter, Editorial / Commentary
    • The future of breast cancer systemic therapy: the next 10 years.
    • Telli ML, Sledge GW.
    • J Mol Med (Berl). 2015 Feb;93(2):119-25. doi: 10.1007/s00109-014-1238-y. Epub 2015 Jan 9.
    • Review
    • The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
    • Zhai L, Li S, Li X, Li H, Gu F, Guo X, Liu F, Zhang X, Fu L.
    • Pathol Res Pract. 2015 Feb;211(2):130-7. doi: 10.1016/j.prp.2014.11.004. Epub 2014 Nov 15.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Subtyping of triple-negative breast cancer: Implications for therapy.
    • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.
    • Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16.
    • Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
    • Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z.
    • Int J Cancer. 2015 Jan 1;136(1):204-11. doi: 10.1002/ijc.28966. Epub 2014 May 23.
    • Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.
    • Lord CJ, Tutt AN, Ashworth A.
    • Annu Rev Med. [2015 Jan;]66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.
    • Review
    • Biological and clinical significance of PARP1 protein expression in breast cancer.
    • Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.
    • Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.
    • Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.
    • Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.
    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
    • Somyajit K, Mishra A, Jameei A, Nagaraju G.
    • Carcinogenesis. 2015 Jan;36(1):13-24. doi: 10.1093/carcin/bgu211. Epub 2014 Oct 7.
    • BRCA2-associated therapy-related acute myeloid leukemia.
    • Rashidi A, Amarillo I, Fisher SI.
    • Med Oncol. 2015 Jan;32(1):371. doi: 10.1007/s12032-014-0371-3. Epub 2014 Nov 27.
    • Letter, Case Report
    • Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
    • Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S.
    • Mol Oncol. 2015 Jan;9(1):204-17. doi: 10.1016/j.molonc.2014.08.001. Epub 2014 Aug 27.
    • An update on PARP inhibitors-moving to the adjuvant setting.
    • Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.
    • Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.
    • Review
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.
    • Zhang L, Fang C, Xu X, Li A, Cai Q, Long X.
    • Biomed Res Int. 2015;2015:357485. doi: 10.1155/2015/357485. Epub 2015 Jan 28.
    • The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.
    • Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
    • Hamilton N, Marquez-Garban D, Mah VH, Elshimali Y, Elashoff D, Garon EB, Vadgama J, Pietras R.
    • Crit Rev Oncog. 2015;20(5-6):373-90. doi: 10.1615/CritRevOncog.v20.i5-6.100.
    • Review
    • Advances in PARP inhibitors for the treatment of breast cancer.
    • Dizdar O, Arslan C, Altundag K.
    • Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.
    • Review
    • Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
    • Tomasz Byrski, Tomasz Huzarski, Rebecca Dent, Elzbieta Marczyk, Marek Jasiowka, Jacek Gronwald, Jerzy Jakubowicz, Cezary Cybulski, Rafal Wisniowski, Dariusz Godlewski, Jan Lubinski, Steven A Narod.
    • Hereditary Cancer in Clinical Practice 2015, 13(Suppl 2):A8; Meeting abstracts from the Annual Conference on Hereditary Cancers 2014. doi:10.1186/1897-4287-13-S2-A8
    • Conference Abstract
    • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
    • Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.
    • BMC Cancer. 2014 Dec 19;14(1):983. doi: 10.1186/1471-2407-14-983.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
    • Pfeifer W, Sokolenko AP, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, Zaitseva OA, Yatsuk OS, Matsko DE, Semiglazova TY, Togo AV, Imyanitov EN.
    • Breast Cancer Res Treat. 2014 Dec;148(3):675-83. doi: 10.1007/s10549-014-3206-1. Epub 2014 Nov 21.
    • [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    • Pernin V, Mégnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J.
    • Cancer Radiother. 2014 Dec;18(8):790-8; quiz 799-802. doi: 10.1016/j.canrad.2014.05.012. Epub 2014 Oct 17.
    • Review, [Article in French]
    • Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking.
    • Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, Moore JH, Saykin AJ.
    • Psychooncology. 2014 Dec;23(12):1382-90. doi: 10.1002/pon.3545. Epub 2014 Apr 30.
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair.
    • Alli E, Solow-Cordero D, Casey SC, Ford JM.
    • Cancer Res. 2014 Nov 1;74(21):6205-15. doi: 10.1158/0008-5472.CAN-14-1716. Epub 2014 Sep 12.
    • TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes.
    • Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.
    • Mol Cancer Res. 2014 Nov;12(11):1597-609. doi: 10.1158/1541-7786.MCR-14-0201. Epub 2014 Aug 7.
    • Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
    • Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H.
    • Int J Cancer. 2014 Oct 15;135(8):1898-910. doi: 10.1002/ijc.28831. Epub 2014 Mar 20.
    • Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
    • Audeh MW.
    • Pharmgenomics Pers Med. 2014 Oct 3;7:307-16. doi: 10.2147/PGPM.S39765. eCollection 2014.
    • Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
    • Vulsteke C, Pfeil AM, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Peeters M, van Dam P, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H.
    • Breast Cancer Res Treat. 2014 Oct;147(3):557-70. doi: 10.1007/s10549-014-3105-5. Epub 2014 Aug 29.
    • Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    • García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    • Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.
    • BRCA1 pathway function in basal-like breast cancer cells.
    • Hill SJ, Clark AP, Silver DP, Livingston DM.
    • Mol Cell Biol. 2014 Oct;34(20):3828-42. doi: 10.1128/MCB.01646-13. Epub 2014 Aug 4.
    • Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
    • Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.
    • Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.
    • Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
    • Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, Lubinski J, Narod SA.
    • Breast Cancer Res Treat. 2014 Sep;147(2):401-5. doi: 10.1007/s10549-014-3100-x. Epub 2014 Aug 17.
    • Synergistic therapeutic effect of cisplatin and phosphatidylinositol 3-kinase (PI3K) inhibitors in cancer growth and metastasis of Brca1 mutant tumors.
    • Vassilopoulos A, Xiao C, Chisholm C, Chen W, Xu X, Lahusen TJ, Bewley C, Deng CX.
    • J Biol Chem. 2014 Aug 29;289(35):24202-14. doi: 10.1074/jbc.M114.567552. Epub 2014 Jul 8.
    • Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
    • Kriege M, Hollestelle A, Jager A, Huijts PE, Berns EM, Sieuwerts AM, Meijer-van Gelder ME, Collée JM, Devilee P, Hooning MJ, Martens JW, Seynaeve C.
    • Br J Cancer. 2014 Aug 26;111(5):1004-1013. doi: 10.1038/bjc.2014.306. Epub 2014 Jun 10.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: risk for second primary in CHEK2?

    Subject: Risk of 2nd breast cancer in CHEk2 family

    • Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
    • Yamamoto KN, Hirota K, Takeda S, Haeno H.
    • PLoS One. 2014 Aug 26;9(8):e105724. doi: 10.1371/journal.pone.0105724. eCollection 2014.
    • Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
    • Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.
    • Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.
    • Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    • Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.
    • Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
    • Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
    • Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ.
    • Breast Cancer Res Treat. 2014 Aug;147(1):81-94. doi: 10.1007/s10549-014-3085-5. Epub 2014 Aug 8.
    • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
    • Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA.
    • Breast Cancer Res Treat. 2014 Aug;146(3):557-66. doi: 10.1007/s10549-014-3039-y. Epub 2014 Jul 8.
    • Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    • Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.
    • Oncotarget. 2014 Jul 30;5(14):5637-50.
    • Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
    • Drost R, Jonkers J.
    • Oncogene. 2014 Jul 17;33(29):3753-63. doi: 10.1038/onc.2013.329. Epub 2013 Aug 19.
    • Review
    • Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    • Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE.
    • Breast Cancer Res Treat. 2014 Jul;146(1):175-82. doi: 10.1007/s10549-014-2995-6. Epub 2014 May 18.
    • The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
    • To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT.
    • Cancer Prev Res (Phila). 2014 Jul;7(7):698-707. doi: 10.1158/1940-6207.CAPR-14-0047. Epub 2014 May 9.

    Letter, Comment:

    PARP inhibitors for chemoprevention--letter.

    Letter, Reply:

    PARP inhibitors for chemoprevention--reply.

    • Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
    • Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C.
    • Breast Cancer Res. 2014 Jun 24;16(3):R67. doi: 10.1186/bcr3682.
    • Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    • Watkins JA, Irshad S, Grigoriadis A, Tutt AN.
    • Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
    • Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
    • Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J.
    • Ann Oncol. 2014 Jun;25(6):1152-8. doi: 10.1093/annonc/mdu134. Epub 2014 Apr 1.

    Letter, Comment:

    Treating breast cancer with trabectedin: a new arsenal.

    Letter, Reply:

    Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik.

    • Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases.
    • Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ.
    • Clin Breast Cancer. 2014 Jun;14(3):182-90. doi: 10.1016/j.clbc.2013.12.002. Epub 2013 Dec 27.
    • Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    • Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q.
    • Oncotarget. 2014 May 30;5(10):3375-85.
    • Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
    • Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
    • J Natl Cancer Inst. 2014 May 19;106(6). pii: dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.
    • On the road to PARPi-platin.
    • Bookman MA.
    • J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun.
    • Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    • Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.
    • Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.

    Editorial:

    Tumor homologous recombination deficiency assays: another step closer to clinical application?

    • Systemic treatment strategies for triple-negative breast cancer.
    • Yadav BS, Sharma SC, Chanana P, Jhamb S.
    • World J Clin Oncol. 2014 May 10;5(2):125-33. doi: 10.5306/wjco.v5.i2.125.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
    • Sun Y, Ding H, Liu X, Li X, Li L.
    • Tumour Biol. 2014 May;35(5):4469-77. doi: 10.1007/s13277-013-1589-y. Epub 2014 Jan 14.
    • Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer.
    • Shakir AR.
    • Case Rep Oncol. 2014 Apr 9;7(1):252-9. doi: 10.1159/000362443. eCollection 2014.
    • Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With BRCA Mutations.
    • Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.
    • J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.

    Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.

    • BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    • Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R.
    • Cancer Chemother Pharmacol. 2014 Apr;73(4):771-8. doi: 10.1007/s00280-014-2404-1. Epub 2014 Feb 14.
    • Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer.
    • Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.
    • Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.
    • Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
    • Pfeil AM, Vulsteke C, Paridaens R, Dieudonné AS, Pettengell R, Hatse S, Neven P, Lambrechts D, Szucs TD, Schwenkglenks M, Wildiers H.
    • BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201.
    • The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    • Xia Q, Cai Y, Peng R, Wu G, Shi Y, Jiang W.
    • Int J Oncol. 2014 Mar;44(3):735-44. doi: 10.3892/ijo.2013.2240. Epub 2013 Dec 31.
    • Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?
    • Raphael J, Mazouni C, Caron O, Ferchiou M, Delaloge S.
    • Med Oncol. 2014 Mar;31(3):850. doi: 10.1007/s12032-014-0850-6. Epub 2014 Jan 22.
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    • De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.
    • Cell Death Dis. 2014 Feb 20;5:e1076. doi: 10.1038/cddis.2014.30.
    • Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
    • Bouwman P, Jonkers J.
    • Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
    • PARP inhibitors for anticancer therapy.
    • Curtin N.
    • Biochem Soc Trans. 2014 Feb;42(1):82-8. doi: 10.1042/BST20130187.
    • Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.
    • Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N.
    • Breast Cancer Res Treat. 2014 Feb;144(1):133-42. doi: 10.1007/s10549-014-2842-9. Epub 2014 Jan 30.
    • Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
    • Suspitsin EN, Yanus GA, Sokolenko AP, Yatsuk OS, Zaitseva OA, Bessonov AA, Ivantsov AO, Heinstein VA, Klimashevskiy VF, Togo AV, Imyanitov EN.
    • Med Oncol. 2014 Feb;31(2):828. doi: 10.1007/s12032-013-0828-9. Epub 2014 Jan 12.
    • Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.
    • Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA.
    • Oncol Rep. 2014 Feb;31(2):551-6. doi: 10.3892/or.2013.2902. Epub 2013 Dec 5.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    • Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.
    • Breast Cancer. 2014 Jan;21(1):75-85. doi: 10.1007/s12282-012-0356-z. Epub 2012 Mar 28.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Targeting the BRCA1/2 Tumor Suppressors.
    • Rosen EM, Pishvaian MJ.
    • Curr Drug Targets. 2014 Jan;15(1):17-31.
    • Review
    • DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer.
    • Pinto R, De Summa S, Pilato B, Tommasi S.
    • Curr Mol Med. 2014 Jan;14(1):45-57.
    • Review
    • Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    • De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    • Neoplasia. 2014 Jan;16(1):43-72.
    • Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
    • Telli M.
    • Am Soc Clin Oncol Educ Book. 2014:e37-42. doi: 10.14694/EdBook_AM.2014.34.e37.
    • BRCA1 as Target for Breast Cancer Prevention and Therapy.
    • Romagnolo AP, Romagnolo DF, Selmin OI.
    • Anticancer Agents Med Chem. 2014;15(1):4-14.
    • Review
    • Drug target strategies in breast cancer treatment: recent developments.
    • Mayank, Jaitak V.
    • Anticancer Agents Med Chem. 2014;14(10):1414-27.
    • Review
    • Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.
    • Zghair AN, Sharma R, Sharma AK.
    • Curr Pharm Biotechnol. 2014;15(12):1113-24.
    • Review
    • Epigenetic mechanisms of breast cancer: an update of the current knowledge.
    • Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, Bignon YJ, Bernard-Gallon D.
    • Epigenomics. 2014;6(6):651-64. doi: 10.2217/epi.14.59.
    • Review
    • Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
    • Bieche I, Pennaneach V, Driouch K, Vacher S, Zaremba T, Susini A, Lidereau R, Hall J.
    • Int J Cancer. 2013 Dec 15;133(12):2791-2800. doi: 10.1002/ijc.28304. Epub 2013 Aug 9.
    • Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    • Curtin NJ, Szabo C.
    • Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
    • Appraising iniparib, the PARP inhibitor that never was--what must we learn?
    • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.
    • Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.
    • Review
    • ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    • Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S.
    • J Exp Clin Cancer Res. 2013 Nov 19;32(1):95. doi: 10.1186/1756-9966-32-95.
    • PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
    • Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.
    • Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013.
    • Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
    • Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.
    • J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

    Letter, Comment:

    Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.

    • Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
    • Lord CJ, Ashworth A.
    • Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.
    • Review
    • The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
    • Huszno J, Budryk M, Kołosza Z, Nowara E.
    • Oncology. [2013 Nov;]85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.
    • Young breast cancer patients' involvement in treatment decisions: the major role played by decision-making about surgery.
    • Seror V, Cortaredona S, Bouhnik AD, Meresse M, Cluze C, Viens P, Rey D, Peretti-Watel P.
    • Psychooncology. 2013 Nov;22(11):2546-56. doi: 10.1002/pon.3316. Epub 2013 Jun 7.
    • Novel strategies towards the use of anti-angiogenic agents in breast cancer.
    • Bakker JL, Meijers-Heijboer H, Verheul H.
    • Eur J Pharmacol. 2013 Oct 5;717(1-3):36-9. doi: 10.1016/j.ejphar.2013.03.035. Epub 2013 Mar 30.
    • Review
    • PARP inhibitors are not all equal.
    • Dent P.
    • Cancer Biol Ther. 2013 Oct 1;14(10):873-4. doi: 10.4161/cbt.26160. Epub 2013 Aug 26.

    Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

    • BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
    • Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.
    • Nucleic Acids Res. 2013 Oct 1;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.
    • Targeted therapy for breast cancer.
    • Mohamed A, Krajewski K, Cakar B, Ma CX.
    • Am J Pathol. 2013 Oct;183(4):1096-112. doi: 10.1016/j.ajpath.2013.07.005. Epub 2013 Aug 27.
    • Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
    • Francken AB, Schouten PC, Bleiker EM, Linn SC, Rutgers EJ.
    • Breast. 2013 Oct;22(5):561-8. doi: 10.1016/j.breast.2013.07.045. Epub 2013 Aug 21.
    • Review
    • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    • Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.
    • Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.
    • Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody.
    • Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G.
    • Mol Cancer Ther. 2013 Oct;12(10):2043-54. doi: 10.1158/1535-7163.MCT-13-0108. Epub 2013 Jul 19.
    • Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
    • Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J.
    • Breast Cancer Res. [2013 Sep 25;]15(5):R88.
    • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
    • Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL.
    • J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.

    Press: Tamoxifen Cuts Risk for Breast Cancer in BRCA Carriers. (Medscape)

    Press: Tamoxifen for prevention in high-risk breast cancer. (Medical News Today)

    Press: In BRCA, Tamoxifen May Reduce Contralateral Breast Cancer Risk. (Clinical Oncology News)

    • Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.
    • Cardoso-Filho C, Sarian LO, de Oliveira CB, da Silveira Bossi L, Lourenço GJ, Lima CS, Gurgel MS.
    • Cancer Chemother Pharmacol. 2013 Sep;72(3):529-35. doi: 10.1007/s00280-013-2221-y. Epub 2013 Jul 11.
    • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.
    • Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
    • Triple-negative breast cancer: new perspectives for novel therapies.
    • Mahamodhossen YA, Liu W, Rong-Rong Z.
    • Med Oncol. 2013 Sep;30(3):653. doi: 10.1007/s12032-013-0653-1. Epub 2013 Jul 4.
    • Review
    • Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    • Yi YW, Kang HJ, Kim HJ, Hwang JS, Wang A, Bae
    • Mol Carcinog. 2013 Sep;52(9):667-75. doi: 10.1002/mc.21905. Epub 2012 Apr 4.
    • Relapsed triple-negative breast cancer: challenges and treatment strategies.
    • Guarneri V, Dieci MV, Conte P.
    • Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6.
    • Review
    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.
    • Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM.
    • Invest New Drugs. 2013 Aug;31(4):949-58. doi: 10.1007/s10637-012-9922-7. Epub 2013 Jan 13.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    • Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.
    • Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.
    • Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    • Chalasani P, Livingston R.
    • Oncologist. [2013 Aug;]18(8):909-16. doi: 10.1634/theoncologist.2013-0039. Epub 2013 Jul 23.
    • RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    • Lok BH, Carley AC, Tchang B, Powell SN.
    • Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • PARP Inhibitor Research Update.
    • Susan Domchek.
    • FORCE. Be Empowered Webinars. 2013 Jun 27.
    • Promise for BRCA-defective cancers.
    • Nicola McCarthy.
    • Nature Reviews Cancer. 2013 Jun 24;13(7):439. doi:10.1038/nrc3552.
    • Conference report
    • The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
    • Nakles RE, Kallakury BV, Furth PA.
    • Am J Pathol. 2013 Jun;182(6):1976-85. doi: 10.1016/j.ajpath.2013.02.006. Epub 2013 May 8.

    Commentary:

    Anticancer activities of PPARγ in breast cancer are context-dependent.

    • Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
    • Xu Y, Diao L, Chen Y, Liu Y, Wang C, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Deng D, Narod SA, Xie Y.
    • Ann Oncol. 2013 Jun;24(6):1498-505. doi: 10.1093/annonc/mdt011. Epub 2013 Feb 13.
    • Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    • Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H.
    • Ann Oncol. 2013 Jun;24(6):1513-25. doi: 10.1093/annonc/mdt008. Epub 2013 Feb 7.
    • CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.
    • Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC.
    • Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5.
    • BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    • D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ.
    • Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    • Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ.
    • Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349.

    Comment:

    PARP inhibitors are not all equal.

    • Pharmacogenomics of endocrine therapy in breast cancer.
    • Ingle JN.
    • J Hum Genet. 2013 Jun;58(6):306-312. doi: 10.1038/jhg.2013.35. Epub 2013 May 2.
    • Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    • Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.
    • J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.
    • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review.
    • Kandula M, Ch KK, Ys AR.
    • World J Oncol. 2013 Jun;4(3):137-141. doi: 10.4021/wjon681e. Epub 2013 Jul 15.
    • From AACR-Chemotherapy: Combination therapy shows activity in BRCA-mutant tumours.
    • [No author given]
    • Nat Rev Clin Oncol. 2013 May;10(5):250. doi: 10.1038/nrclinonc.2013.61.
    • Research highlight
    • Drug Combo Effective in Incurable BRCA-Deficient Cancers.
    • Nick Mulcahy.
    • Medscape Medical News. American Association for Cancer Research (AACR) 104th Annual Meeting. 2013 Apr 19.
    • Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
    • Narod SA, Metcalfe K, Lynch HT, Ghadirian P, Robidoux A, Tung N, Gaughan E, Kim-Sing C, Olopade OI, Foulkes WD, Robson M, Offit K, Jakubowska A, Byrski T, Huzarski T, Sun P, Lubinski J.
    • Breast Cancer Res Treat. 2013 Feb;138(1):273-9. doi: 10.1007/s10549-013-2429-x. Epub 2013 Feb 6.
    • Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors.
    • Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.
    • Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

    Commentary:

    Mechanisms of resistance to PARP inhibitors--three and counting.

    • Triple Negative Breast Cancer - An Overview.
    • Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN.
    • Hereditary Genet. 2013;2013(Suppl 2). pii: 001.
    • Treating breast cancer in the 21st century: emerging biological therapies.
    • Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ.
    • J Cancer. 2013;4(2):117-32. doi: 10.7150/jca.4925. Epub 2013 Jan 11.

Continue to Older References